Dysregulated vitamin D signaling in Hashimoto's thyroiditis: an integrated transcriptomic study in a Korean cohort.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as an observational study.

This retrospective observational study was conducted to investigate serum vitamin D levels and dysregulation of vitamin D signaling pathways in patients with HT.

Why It Was Studied

Hashimoto's thyroiditis (HT) is the most common thyroid disease leading to hypothyroidism in developed countries.

Recent studies have highlighted vitamin D as a potential risk factor or therapeutic agent for HT owing to its role in modulating immune responses, although concrete evidence has not been presented.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Patients who underwent thyroid surgery for various thyroid neoplasm with or without HT were recruited.

The researchers analyzed serum thyroid biomarkers, including serum vitamin D, anti-thyroglobulin (TG) antibody, and anti-thyroid peroxidase (TPO) antibody for patients with HT.

How the Study Was Run

Using RNA-seq, the gene expression profile of thyroid tissue and the potential correlation between HT and vitamin D levels or its signaling were investigated.

What Was Measured

Topics PubMed links to this paper include Vitamin D, Hashimoto Disease, Republic of Korea, Signal Transduction, Transcriptome, Gene Expression Profiling and Receptors, Calcitriol.

The authors tagged it with the keywords Hashimoto’s thyroiditis, RNA-seq, autoimmune thyroid diseases and vitamin D regulatory pathway.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.